CCM
KYTX icon

Catalio Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Catalio Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-586,909
Closed -$3.52M – 52
2025
Q3 		$3.52M Hold
586,909
– – 0.65% 29
2025
Q2 		$1.8M Hold
586,909
– – 0.38% 30
2025
Q1 		$1.13M Hold
586,909
– – 0.28% 29
2024
Q4 		$2.2M Buy
+586,909
New +$2.81M 0.48% 26

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Catalio Capital Management's KYTX Position: Q4 2025 in Review

Catalio Capital Management sold out of Kyverna Therapeutics (KYTX) in Q4 2025, closing a stake of 586,909 shares — an estimated $3.52M sold.

Catalio Capital Management first reported a position in KYTX in Q4 2024 and held it in 4 quarters. The position peaked at $3.52M in Q3 2025. 99 funds tracked by Wall St. Rank hold KYTX as of Q4 2025.

  • Catalio Capital Management reported no remaining Kyverna Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Catalio Capital Management sold 586,909 Kyverna Therapeutics shares in Q4 2025, an estimated $3.52M.
  • Catalio Capital Management first reported a position in Kyverna Therapeutics in Q4 2024 and held it in 4 quarters.
  • Catalio Capital Management's Kyverna Therapeutics position peaked at $3.52M in Q3 2025.
  • 99 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2025.

Based on Catalio Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.